Postnatal Bone Growth: Growth Plate Biology, Modeling, and Remodeling

Pediatric Bone: Biology & Diseases

Volumn , Issue , 2003, Pages 119-133

  Karsenty, Gerard ^a   Kronenberg, Henry M ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70449535310     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012286551-0/50006-3     Document Type: Chapter

References (132)

1. Bi W., Deng J.M., Zhang Z., Behringer R.R., de Crombrugghe B. Sox9 is required for cartilage formation. Nature Genet. 1999, 22:85-99.
2. Horton W.E., Feng L., Adams C. Chondrocyte apoptosis in development, aging and disease. Matrix Biol. 1998, 17(2):107-115.
3. St.-Jacques B., Hammerschmidt M., McMahon A. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 1999, 13(16):2072-2086.
4. Chung U.I., Schipani E., McMahon A.P., Kronenberg H.M. Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development [see Comments]. J.Clin. Invest. 2001, 107(3):295-304.
5. Hunziker E.B. Mechanism of longitudinal bone growth and its regulation by growth plate chondrocytes. Microsc. Res. Technique 1994, 28(6):505-519.
6. Ducy P., Starbuck M., Priemel M., Shen J., Pinero G., Geoffroy V., et al. A Cbfal-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev. 1999, 13(8):1025-1036.
7. Morriss-Kay G.M. Derivation of the mammalian skull vault. J.Anat. 2001, 199:143-151. (Pts. 1-2).
8. Opperman L.A. Cranial sutures as intramembranous bone growth sites. Dev. Dyn. 2000, 219(4):472-485.
9. Salmon W.D.J. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J.Lab. Clin. Med. 1957, 49:825-836.
10. Daughaday W.H., Hall K., Raben M.S., Salmon W.D., van den Brande J.L., van Wyk J.J. Somatomedin: Proposed designation for sulphation factor. Nature 1972, 235(5333):107.
11. Salmon W.D., Burkhalter V.J. Stimulation of sulfate and thymidine incorporation into hypophysectomized rat cartilage by growth hormone and insulin-like growth factor-I in vitro: The somat. J.Lab. Clin. Med. 1997, 129(4):430-438.
12. Zhou Y., Xu B.C., Maheshwari H.G., He L., Reed M., Lozykowski M., et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc. Natl. Acad. Sci. USA 1997, 94(24):13215-13220.
13. Laron Z. Insulin-like growth factor 1 (IGF-1): A growth hormone. Mol. Pathol 2001, 54(5):311-316.
14. Coschigano K.T., Clemmons D., Bellush L.L., Kopchick J.J. Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology 2000, 141(7):2608-2613.
15. Chandrashekar V., Bartke A., Coschigano K.T., Kopchick J.J. Pituitary and testicular function in growth hormone receptor gene knockout mice. Endocrinology 1999, 140(3):1082-1088.
16. Sjogren K., Bohlooly Y.M., Olsson B., Coschigano K., Tornell J., Mohan S., et al. Disproportional skeletal growth and markedly decreased bone mineral content in growth hormone receptor -/- mice. Biochem. Biophys. Res. Commun. 2000, 267(2):603-608.
17. Lupu F., Terwilliger J.D., Lee K., Segre G.V., Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev. Biol. 2001, 229:141-162.
18. Rosenbloom A.L., Guevara-Aguirre J., Rosenfeld R.G., Francke U. Growth hormone receptor deficiency in Ecuador. J.Clin. Endocrinol Metab. 1999, 84(12):4436-4443.
19. Baker J., Liu J.P., Robertson E.J., Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993, 75:73-82.
20. Liu J.P., Baker J., Perkins A.S., Robertson E.J., Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igflr). Cell 1993, 75:59-72.
21. Powell-Braxton L., Hollingshead P., Warburton C., Dowd M., Pitts-Meek S., Dalton D., et al. IGF-I is required for normal embryonic growth in mice. Genes Dev. 1993, 7(12B):2609-2617.
22. Woods K.A., Camacho-Hubner C., Savage M.O., Clark A.J. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene [see Comments]. N.Engl. J. Med. 1996, 335(18):1363-1367.
23. Wang J., Zhou J., Bondy C.A. Igfl promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy. FASEB J. 1999, 13(14):1985-1990.
24. Ohlsson C., Bengtsson B.A., Isaksson O.G., Andreassen T.T., Slootweg M.C. Growth hormone and bone. Endocr. Rev. 1998, 19:55-79.
25. Ohlsson C., Nilsson A., Isaksson O., Lindahl A. Growth hormone induces multiplication of the slowly cycling germinal cells of the rat tibial growth plate. Proc. Natl. Acad. Sci. USA 1992, 89(20):9826-9830.
26. Reinecke M., Schmid A.C., Heyberger-Meyer B., Hunziker E.B., Zapf J. Effect of growth hormone and insulin-like growth factor I (IGF-I) on the expression of IGF-I messenger ribonucleic acid and peptide in rat tibial growth plate. Endocrinology 2000, 141(8):2847-2853.
27. Sjogren K., Liu J.L., Blad K., Skrtic S., Vidal O., Wallenius V., et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc. Natl. Acad. Sci. USA 1999, 96(12):7088-7092.
28. Yakar S., Liu J.L., Stannard B., Butler A., Accili D., Sauer B., et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. USA 1999, 96(13):7324-7329.
29. DeChiara T.M., Efstratiadis A., Robertson E.J. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 1990, 345(6270):78-80.
30. Louvi A., Accili D., Efstratiadis A. Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev. Biol. 1997, 189:33-48.
31. von Horn H., Ekstrom C., Ellis E., Olivecrona H., Einarsson C., Tally M., et al. GH is a regulator of IGF2 promoter-specific transcription in human liver. J.Endocrinol 2002, 172(3):457-465.
32. Ornitz D., Marie P. FGF signaling pathways in endo-chondral and intramembranous bone development and human genetic disease. Genes Dev. 2002, 16(12):1446-1465.
33. Ornitz D.M., Itoh N. Fibroblast growth factors. Genome Biol 2001, 2(3).
34. Xu X., Weinstein M., Li C., Deng C. Fibroblast growth factor receptors (FGFRs) and their roles in limb development. Cell Tissue Res. 1999, 296:33-43.
35. Colvin J.S., Bohne B.A., Harding G.W., McEwen D.G., Ornitz D.M. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nature Genet. 1996, 12(4):390-397.
36. Deng C., Wynshaw-Boris A., Zhou F., Kuo A., Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 1996, 84(6):911-921.
37. Sahni M., Ambrosetti D.C., Mansukhani A., Gertner R., Levy D., Basilico C. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 1999, 13(11):1361-1366.
38. Sahni M., Raz R., Coffin J.D., Levy D., Basilico C. STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. Dev. Suppl. 2001, 128(11):2119-2129.
39. Liu Z., Xu J., Colvin J.S., Ornitz D.M. Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev. 2002, 16(7):859-869.
40. Ohbayashi N., Shibayama M., Kurotaki Y., Imanishi M., Fujimori T., Itoh N., et al. FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev. 2002, 16(7):870-879.
41. Arman E., Haffner-Krausz R., Chen Y., Heath J.K., Lonai P. Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development. Proc. Natl. Acad. Sci. USA 1998, 95(9):5082-5087.
42. Arman E., Haffner-Krausz R., Gorivodsky M., Lonai P. Fgfr2 is required for limb outgrowth and lung-branching morphogenesis. Proc. Natl. Acad. Sci. USA 1999, 96(21):11895-11899.
43. Ornitz D.M. GFG and FGF receptor signaling in skeletal development and genetic disease. Program and Abstracts, Endo 2002 2002, 54. Abstact #S56-1.
44. Baitner A.C., Maurer S.G., Gruen M.B., Di Cesare P.E. The genetic basis of the osteochondrodysplasias. J.Pediatr. Orthop. 2000, 20(5):594-605.
45. Zhou Y.X., Xu X., Chen L., Li C., Brodie S.G., Deng C.X. A Pro250Arg substitution in mouse Fgfrl causes increased expression of Cbfal and premature fusion of calvarial sutures. Hum. Mol. Genet. 2000, 9(13):2001-2008.
46. Ducy P., Zhang R., Geoffroy V., Ridall A.L., Karsenty G. Osf2/Cbfal: A transcriptional activator of osteoblast differentiation [see Comments]. Cell 1997, 89(5):747-754.
47. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., et al. Targeted disruption of Cbfal results in a complete lack of bone formation owing to maturational arrest of osteoblasts [see Comments]. Cell 1997, 89(5):755-764.
48. Lemonnier J., Hay E., Delannoy P., Fromigue O., Lomri A., Modrowski D., et al. Increased osteoblast apoptosis in apert craniosynostosis: Role of protein kinase C and interleukin-1. Am. J. Pathol. 2001, 158(5):1833-1842.
49. Montero A., Okada Y., Tomita M., Ito M., Tsurukami H., Nakamura T., et al. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J.Clin. Invest. 2000, 105(8):1085-1093.
50. Stevens D.A., Hasserjian R.P., Robson H., Siebler T., Shalet S.M., Williams G.R. Thyroid hormones regulate hypertrophic chondrocyte differentiation and expression of parathyroid hormone-related peptide and its receptor during endochondral. J.Bone Miner. Res. 2000, 15(12):2431-2442.
51. Burch W.M., Lebovitz H.E. Triiodothyronine stimulation of in vitro growth and maturation of embryonic chick cartilage. Endocrinology 1982, 111(2):462-468.
52. Burch W.M., Lebovitz H.E. Triiodothyronine stimulates maturation of porcine growth-plate cartilage in vitro. J.Clin. Invest. 1982, 70(3):496-504.
53. Robson H., Siebler T., Stevens D.A., Shalet S.M., Williams G.R. Thyroid hormone acts directly on growth plate chondrocytes to promote hypertrophic differentiation and inhibit clonal expansion and cell proliferation. Endocrinology 2000, 141(10):3887-3897.
54. Gauthier K., Plateroti M., Harvey C.B., Williams G.R., Weiss R.E., Refetoff S., et al. Genetic analysis reveals different functions for the products of the thyroid hormone receptor alpha locus. Mol Cell. Biol. 2001, 21(14):4748-4760.
55. Harvey C.B., O'Shea P.J., Scott A.J., Robson H., Siebler T., Shalet S.M., et al. Molecular mechanisms of thyroid hormone effects on bone growth and function. Mol. Genet. Metab. 2002, 75:17-30.
56. Weiss R.E., Refetoff S. Effect of thyroid hormone on growth. Lessons from the syndrome of resistance to thyroid hormone. Endocrinol. Metab. Clin. North Am. 1996, 25(3):719-730.
57. Smith E.P., Boyd J., Frank G.R., Takahashi H., Cohen R.M., Specker B., et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N.Engl J. Med. 1994, 331(16):1056-1061.
58. Carani C., Qin K., Simoni M., Faustini-Fustini M., Serpente S., Boyd J., et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N.Engl. J. Med. 1997, 337(2):91-95.
59. Bilezikian J.P., Morishima A., Bell J., Grumbach M.M. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N.Engl. J. Med. 1998, 339(9):599-603.
60. Grumbach M.M., Auchus R.J. Estrogen: Consequences and implications of human mutations in synthesis and action [see Comments]. J.Clin. Endocrinol. Metab. 1999, 84(12):4677-4694.
61. Warshawsky H. Embryology and development of the skeletal system. The Musculoskeletal System: Embryology, Biochemistry and Physiology 1982, 33-56. Churchill Livingston, Philadelphia.
62. Byers P.H., Steiner R.D. Osteogenesis imperfecta. Annu. Rev. Med. 1992, 43:269-282.
63. Corral D., Amling M., Prienel M., Loyer E., Fuchs S., Ducy P., et al. Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc. Natl Acad. Sci. USA 1998, 95:13835-13840.
64. Ogawa E., Maruyama M., Kagoshima H., Inuzuka M., Lu J., Satake M., et al. PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosohila runt gene and the human AML1 gene. Proc. Natl. Acad. Sci. USA 1993, 90:6859-6863.
65. Levanon D., Negreanu V., Bernstein Y., Bar-Am I., Avivi L., Groner Y. AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics 1994, 23:425-432.
66. Speck N.A., Stacy T. A new transcription factor family associated with human leukemias. CRC Crit. Rev. Eukaryot. Gene Expression 1995, 5:337-364.
67. Gergen J.P., Wieschaus E. Dosage requirements for runt in the segmentation of Drosophila embryos. Cell 1986, 45:289-299.
68. Ducy P., Karsenty G. Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol. Cell. Biol. 1995, 15:1858-1869.
69. Banerjee C., McCabe L.R., Choi J.Y., Hiebert S.W., Stein J.L., Stein G.S., et al. Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex. J.Cell. Biochem. 1997, 66:1-8.
70. Li Y.C., Amling M., Pirro A., Priemel M., Meuse J., Baron R., et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-abla. Endocrinology 1998, 139:4391-4396.
71. Jimenez M.J., Balbin M., Lopez J.M., Alvarez J., Komori T., Lopez-Otin C. Collagenase 3 is a target of Cbfal, a transcription factor of the runt gene family involved in bone formation. Mol. Cell. Biol. 1999, 19:4431-4442.
72. Porte, D., Tuckermann, J., Becker, M., Baumann, B., Teurich, S., Higgins, T., et al. (). Both AP-1 and Cbfal-like factors are required for the induction of interstitial collagenase by parathyroid hormone. Oncogene18, 667-678.
73. Ducy P., Zhang R., Geoffroy V., Rydall A.L., Karsenty G. Osf2/Cbfal, a transcriptional regulator of osteoblast differentiation. Cell 1997, 89:747-754.
74. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., et al. Targeted disruption of Cbfal results in a complete lack of bone formation owing to maturational arrest of osteoblast. Cell 1997, 89:755-764.
75. Otto F., Thornell A.P., Crompton T., Denzel A., Gilmour K.C., Rosewell I.R., et al. Cbfal, a candidate gene for cleido-cranial dysplasia, is essential for osteoblast differentiation and bone development. Cell 1997, 89:765-771.
76. Takeda S., Bonnamy J.P., Owen M.J., Ducy P., Karsenty G. Continuous expression of Cbfal in non-hypertrophic chondrocytes uncovers its ability to induce hypertrophic chondro-cytes differentiation and partially rescue. Genes Dev. 2001, 15:467-481.
77. Sillence D.O., Ritchie H.E., Selby P.B. Animal model: Skeletal anomalies in mice with cleidocranial dysplasia. Am. J. Med. Genet. 1987, 27:75-85.
78. Lee B., Thirunavukkararsu K., Zhou L., Pastore L., Baldini A., Hecht J., et al. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/Cbfal in cleidocranial dysplasia. Nature Genet. 1997, 16:307-310.
79. Mundlos S., Otto F., Mundlos C., Mulliken J.B., Aylsworth A.S., Albright S., et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997, 89:773-779.
80. Ducy P., Starbuck M., Priemel M., Shen J., Pinero G., Geoffroy V., et al. A Cbfal-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev. 1999, 13:1025-1036.
81. Bitgood M.J., McMahon A.P. Hedgehog and BMP genes are coexpressed at many diverse sites of cell-cell interaction in the mouse embryo. Dev. Biol. 1995, 172:126-138.
82. Vortkamp A., Lee K., Lanske B., Segre G.V., Kronenberg H.M., Tabin C.J. Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 1996, 273(5275):613-622.
83. St.-Jacques B., Hammerschmidt M., McMahon A.P. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 1999, 13:2072-2086.
84. Chuang P.T., McMahon A.P. Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein. Nature 1999, 397:617-621.
85. Hogan B.L.M. Bone morphogenetic proteins: Multifunctional regulators of vertebrate development. Genes Dev. 1996, 10:1580-1594.
86. Yoshida Y., Tanaka S., Umemori H., Minowa O., Usui M., Ikematsu N., et al. Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell 2000, 103(7):1085-1097.
87. Shimmel M.J., Ferguson E.L., Childs S.R., O'Connor M.B. The Drosophila dorsal-ventral patterning gene tolloid is related to human bone morphogenetic protein 1. Cell 1991, 67:469-481.
88. Suzuki N., Labosky P.A., Furuta Y., Hargett L., Dunn R., Fogo A.B., et al. Failure of ventral body wall closure in mouse embryos lacking a procollagen C-proteinase encoded by Bmpl, a mammalian gene related to Drosophila tolloid. Development 1996, 122:3587-3595.
89. Lee S., Solow-Cordero D.E., Kessler E., Takahara K., Greenspan D.S. Transforming growth factor-beta regulation of bone morphogenetic protein-1/procollagen C-proteinase and related proteins in fibrogenic cells and keratinocytes. J.Biol Chem. 1997, 272:19056-19066.
90. Erlebacher A., Derynck R. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like pheno-type. J.Cell Biol. 1996, 132:195-210.
91. Erlebacher A., Filvaroff E.H., Ye J.Q., Derynck R. Osteoblastic responses to TGF-beta during bone remodeling. Mol. Cell. Biol. 1998, 9:1903-1918.
92. Sharpe C., Lawrence N., Arias A.F. Wnt signalling: A theme with nuclear variations. Bioesssays 2001, 23:311-318.
93. Somer H., Palotie A., Somer M., Hoikka V., Peltonen L. Osteoporosis-pseudoglioma syndrome: Clinical, morphological, and biochemical studies. J.Med. Genet. 1988, 25:543-549.
94. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107(4):513-523.
95. Tamai K., Semenov M., Kato Y., Spokony R., Liu C., Katsuyama Y., et al. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000, 407:530-535.
96. Mundy G.R., Boyce B., Yoneda T., Bonewald L.F., Roodman G.D. Cytokines and Bone Remodeling 1996, Academic Press, New York.
97. Pacifici R. Cytokines, estrogen, and postmenopausal osteoporosis-The second decade. Endocrinology 1998, 139:2659-2661.
98. Chorev M., Rosenblat M. Parathyroid hormone: Structure-function relations and analog design. Principles of Bone Biology 1996, 305-323. Academic Press, San Diego. J.P. Bilezikian, L.G. Raisz, G.A. Rodan (Eds.).
99. Potts J.T., Juppner H. Parathyroid hormone and parathyroid hormone-related peptide in calcium homeostasis, bone metabolism and bone development: the proteins, their genes and recept. Metabolic Bone Disease and Clinically Related Disorders 1998, 52-94. Academic Press, San Diego. A. Press (Ed.).
100. Friedman J.M. Obesity in the new millennium. Nature 2000, 404:632-634.
101. Elmquist J.K., Maratos-Flier E., Saper C.V., Flier J.S. Unraveling the central nervous system pathways underlying responses to leptin. Nat. Neuro set 1998, 6:445-450.
102. Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil T., et al. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 2000, 100:197-207.
103. Westvik J. Radiological features in generalized lipody-strophy. Acta Paediatr. Suppl. 1996, 13:44-51.
104. Frederick R.C., Hamann A., Anderson S., Lollmann B., Lowell B.B., Flier J.S. Leptin levels reflect body lipid content in mice: Evidence for diet-induced resistance to leptin action. Nat. Med. 1995, 12.
105. Klemsz M.J., McKercher S.R., Celada A., Van Beveren C., Maki R.A. Themacrophage and B cell-specific transcription factor PU.l is related to the ets oncogene. Cell 1990, 61:113-124.
106. Tondravi M.M., McKercher S.R., Anderson K., Erdmann J.M., Quiroz M., Maki R., et al. Osteopetrosis in mice lacking hematopoietic transcription factor PU.l. Nature 1997, 386:81-84.
107. Grigoriadis A.E., Wang Z.Q., Wagner E.F. Fos and bone cell development: Lessons from a nuclear oncogene. Trends Genet. 1995, 11:436-441.
108. Johnson R.S., Spiegelman B.M., Papaioannou V. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 1992, 71:577-586.
109. Wang Z.Q., Ovitt C., Grigoriadis A.E., Mohle-Steinlein U., Ruther U., Wagner E.F. Bone and hematopoietic defects in mice lacking c-fos. Nature 1992, 360:741-745.
110. Grigoriadis A.E., Wang Z.Q., Cecchini M.G., Hofstetter W., Felix R., Fleisch H.A., et al. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994, 266:443-448.
111. Verma I.M., Stevenson J.K., Schwarz E.M., Van Antwerp D., Miyamoto S. Rel/NF-Kb/lKB family: Intimate tales of association and dissociation. Genes Dev. 1995, 9:2723-2735.
112. Franzoso G., Carlson L., Xing L., Poljak L., Shores E.W., Brown K.D., et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 1997, 11:3482-3496.
113. Gerondakis S., Grumont R., Rourke I., Grossmann M. The regulation and roles of Rel/NF-KB transcription factors during lymphocyte activation. Curr. Opin. Immunol. 1998, 10:353-359.
114. Hertwig P. Neue mutationen und kopplungsgruppen bei der hausmaus. Z.Indukt. Abstammungs-Verebungsl. 1942, 80:220-246.
115. Hodgkinson C.A., Moore K.J., Nakayama A., Steingrimsson E., Copeland N.G., Jenkins N.A., et al. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic helix-loop-helix zipper protein. Cell 1993, 74:395-404.
116. Marks S.C.J., Lane P.W. Osteopetrosis, a new recessive skeletal mutation on chromosome 12 of the mouse. J.Heredity 1976, 67:11-18.
117. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
118. Lagasse E., Weissman I.L. Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice. Cell 1997, 89:1021-1031.
119. Simonet S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
120. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998, 139:442-444.
121. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegrin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12:1260-1268.
122. Mizuno A., Amizuka N., Irie K., Murakami A., Fujise N., Kanno T., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 1998, 247:610-615.
123. Burgess T.L., Qian Y., Kaufman S., Ring B.D., Van G., Capparelli C., et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J.Cell Biol. 1999, 145:527-538.
124. Dougall W.C., Mglaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999, 13:2412-2424.
125. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., et al. A homologue of the TNF receptor and it ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
126. Wong B.R., Josien R., Lee S.Y., Vologodskaia M., Steinman R.M., Choi Y. The TRAF family of signal transducers mediates NF-kB activation by the TRANCE receptor. J.Biol. Chem. 1998, 273:28355-28359.
127. Darnay B.J., Ni J., Moore P.A., Aggarwal B.B. Activation of NF-KB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-KB inducing kinase. Identification of a novel TRAF6 inte. J.Biol. Chem. 1999, 274:7724-7731.
128. Lomaga M.A., Yeh W.C., Sarosi I., et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 1999, 13:1015-1024.
129. Kawasaki K., Gao H., Yokose S., Kaji Y., Nakamura T., Suda T., et al. Osteoclasts are present in gp 130-deficient mice. Endocrinology 1997, 138:4959-4965.
130. Brugge J., Cotton P., Lustig A., Yonemoto W., Lipsich L., Coussens P., et al. Characterization of the altered form of the c-src gene product in neuronal cells. Genes Dev. 1987, 1:287-296.
131. Boyce B., Yoneda T., Lowe C., Soriano P., Mundy G.R. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J.Clin. Invest. 1992, 90:1622-1627.
132. Suda T., Udagawa N., Takahashi N. Cells of bone: Osteoclast generation. Principles of Bone Biology 1996, 87-102. Academic Press, San Diego. J.P. Bilezikian, L.G. Raisz, G.A. Rodan (Eds.).